Sugi Predict

Sugi Predict / Compounds / SCHEMBL188546

SCHEMBL188546

SCHEMBL188546

CC(C)C(=O)N1CCN(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.49
▸ HTR1A P08908 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ CHRNB3 Q05901 1/20 0.43
▸ CHRNA6 Q15825 1/20 0.43
▸ CHRM1 P11229 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CHRM3 P20309 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12308331 0.91 HTT (0.52) CYP1A2TDP1HSD17B10HTR1ANPC1
SCHEMBL22753493 0.89 CHRNB2 (0.50) MAPTCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL674660 0.89 — —
SCHEMBL4546617 0.89 CHRNB2 (0.50) MAPTCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL7904346 0.83 CYP1A2 (0.52) CYP1A2TDP1HSD17B10HTR1ANPC1
SCHEMBL17708305 0.83 CYP1A2 (0.52) CYP1A2TDP1HSD17B10HTR1ANPC1
SCHEMBL17708306 0.83 CYP1A2 (0.52) CYP1A2TDP1HSD17B10HTR1ANPC1
SCHEMBL25514015 0.82 ALDH1A1 (0.46) MAPTCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL24302109 0.81 CYP1A2 (0.50) CYP1A2TDP1HSD17B10HTR1ANPC1
SCHEMBL19557946 0.81 CYP1A2 (0.50) CYP1A2TDP1HSD17B10HTR1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 — — US disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-RE50030-E1 Methods to treat lymphoplasmacytic lymphoma DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
US-RE50030-E1 Methods to treat lymphoplasmacytic lymphoma DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-06-27 — — US disclosed
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-06-27 — — US disclosed
US-11912723-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-11912723-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-20070167456-A1 Mercaptoimidazoles as ccr2 receptor antagonists LOMMEN GUY R E 2007-07-19 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 — — US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 — — US disclosed
US-7202381-B2 Compounds as opioid receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2007-04-10 — — US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 — — US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 — — US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 — — US disclosed
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS ROTH GERALD J 2007-01-04 — — US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS KDR, FLT1, EGFR CYP1A2 1517/4885TDP1 1525/4885HSD17B10 4297/4885
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF CYP1A2 3344/4885TDP1 907/4885HSD17B10 2499/4885
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS FGFR1, FGFR2, FGFR3 CYP1A2 2056/4885TDP1 914/4885HSD17B10 1431/4885
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 CYP1A2 4222/4885TDP1 4530/4885HSD17B10 2812/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 CYP1A2 26/4885TDP1 3915/4885HSD17B10 329/4885
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF UACA, ADCYAP1R1, ADCY1 CYP1A2 649/4885TDP1 2510/4885HSD17B10 710/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A CYP1A2 82/4885TDP1 70/4885HSD17B10 663/4885
US-20070167456-A1 Mercaptoimidazoles as ccr2 receptor antagonists CCR2, CCR1, CCR5 CYP1A2 913/4885TDP1 4722/4885HSD17B10 1092/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CYP1A2 763/4885TDP1 2304/4885HSD17B10 501/4885
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors DHPS, DPYD, TYMP CYP1A2 201/4885TDP1 75/4885HSD17B10 1059/4885
US-11912723-B2 KRAS modulators and uses thereof KRAS, NRAS, HRAS CYP1A2 3979/4885TDP1 3181/4885HSD17B10 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.